Integrative Cancer Therapies最新文献

{"title":"Modified Wen Luo Tong Alleviated Chemotherapy-Induced Peripheral Neuropathy via Regulating the CX3CL1/CX3CR1 Axis Through Inhibiting NF-κB and STAT3 Pathways.","authors":"Feize Wu, Jianjing Zhang, Hongyan Wang, Hanwen Luo, Huimiao Lyu, Yawen Zhang, Guanjing Ling, Yilin Li, Jinghua Li, Wei Wang, Qiyan Wang, Linghui Lu","doi":"10.1177/15347354251408836","DOIUrl":"10.1177/15347354251408836","url":null,"abstract":"<p><strong>Background: </strong>Chemotherapy-induced peripheral neuropathy (CIPN) is a serious clinical problem with no widely applicable solutions. Modified Wen Luo Tong (mWLT) was designed specifically for paclitaxel-related CIPN, yet its efficacy and mechanisms remain unclear. This study aimed to investigate its therapeutic effects and potential mechanisms via network pharmacology and animal experimental validation.</p><p><strong>Methods: </strong>Paclitaxel-induced CIPN rat models were treated with mWLT pediluvium. The effect of mWLT was estimated by behavior test. The components and targets of 5 herbs in mWLT were screened from TCMSP and TCMIP databases. CIPN-related targets were retrieved from Genecards and DisGeNET. Networks of gene ontology and pathway associations related to intersection targets were constructed and visualized. A pharmacological network encompassing the intersecting genes and active components was mapped out. A protein-protein interaction network was established for these intersecting targets and visualized using Cytoscape software. Finally, the findings derived from network pharmacology were validated through a series of in vivo experiments, including ELISA, Western Blot, immunohistochemistry and RT-qPCR. Molecular docking was used to predict binding sites between small molecules of mWLT and CX3CR1.</p><p><strong>Results: </strong>mWLT ameliorates mechanical withdrawal threshold of CIPN model rats. Three hundred and three targets of mWLT against CIPN were identified through intersection analysis, and 8 hub targets such as <i>IL6</i>, <i>TNF</i> and <i>STAT3</i> were pinpointed. Enrichment analysis of intersection targets highlighted cellular response to cytokine stimulus, JAK-STAT3 pathway and NF-κB pathway. Thus, we speculated that mWLT may exert its effects by acting on <i>IL6</i> and <i>TNF</i>, subsequently regulating IL6-JAK-STAT3 and TNFα-NF-κB signaling pathway, ultimately mitigating CIPN. Experimental validation demonstrated that mWLT significantly decreased the levels of IL-6, IL-1β and TNF-α in both spinal cord and plasma. Additionally, mWLT downregulated the phosphorylation of JAK, STAT3 and NF-κB in spinal cord. Further analyses using Immunohistochemistry, Western Blot and ELISA confirmed that mWLT reduced the protein expression of CX3CL1. RT-qPCR results revealed downregulation of <i>Cx3cl1</i> and <i>Cx3cr1</i> mRNA level in spinal cord and dorsal root ganglia. Molecular docking predicts 4 potential of compounds derived from mWLT to treat CIPN targeting CX3CR1.</p><p><strong>Conclusion: </strong>mWLT exerts therapeutic effects in the treatment of CIPN by inhibiting CX3CL1/CX3CR1 axis and modulating JAK-STAT3 and NF-κB pathway.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354251408836"},"PeriodicalIF":2.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12775300/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145900321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"Walk for Life\": A Feasibility Randomised Controlled Trial of Guolin Qigong for Fatigue, Sleep Disturbance and Depression Symptom Cluster in Cancer Survivors.","authors":"Sara L K Low, Gwo Fuang Ho, Bingkai Liu, Eng-Siew Koh, Kingsley Agho, Yutong Fei, Xiaoshu Zhu","doi":"10.1177/15347354261442682","DOIUrl":"10.1177/15347354261442682","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the feasibility and the preliminary estimate of effect of a 12-week Guolin Qigong (GQ) intervention, a mind-body exercise, on the fatigue-sleep disturbance-depression symptoms among breast, lung and colon cancer survivors.</p><p><strong>Methods: </strong>Forty-one breast, lung, and colon cancer survivors with moderate to severe fatigue as measured by the Brief Fatigue Index were randomised to a GQ intervention (n = 21) or a waitlist control (n = 20). Outcome measures were assessed at baseline, 6, 12 weeks (post-intervention), and 16 weeks (4 weeks post-intervention). The primary feasibility was assessed using recruitment, retention, class attendance, home practice, safety and quantum of missing data. Secondary outcomes of symptom differences across timepoints in fatigue, sleep, and depression were assessed using a Generalised Estimating Equations (GEE) model with a Gaussian family, independent link, exchangeable correlation structure, and robust variance estimation.</p><p><strong>Results: </strong>Forty-one cancer survivors were successfully recruited with a recruitment rate of 72%. Retention was 95% (GQ) and 80% (control) at Week-12 and Week-16. GQ intervention class attendance was 86% for the 12-weeks duration with home practice averaging 5 day/week and 394 minutes/week. Missing data were less than 10%. There were no intervention-related serious adverse events. From baseline to Week 12 or Week 16, the average decreases in fatigue, sleep quality, and depression were 0.66, 0.11, and 1.79 respectively, after adjusting for gender and cancer-type imbalances.</p><p><strong>Conclusion: </strong>GQ was feasible and safe for cancer survivors with fatigue-sleep disturbance-depression symptoms, within the defined small sample size. A larger randomised trial is needed for statistical validation.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261442682"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13157540/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147814666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Experience of Shared Meditation Involving People With Cancer, Health Professionals and Third Persons: A Qualitative Focus-Group Study.","authors":"Virginie Prevost, Titi Tran, Bénédicte Clarisse, Alexandra Leconte, Marie Fernette, Guillaume Grandazzi, Mylène Gouriot","doi":"10.1177/15347354261439128","DOIUrl":"10.1177/15347354261439128","url":null,"abstract":"<p><p>In recent years, mindfulness-based interventions have gained in popularity as a non-pharmacological intervention for improving well-being in oncology. Our project aims to address the benefit of shared meditation involving patients, medical staff ant third parties (neither patients, nor carers). The intervention programme was based on 12 weekly 2h sessions (including 2 half-day retreats), followed by 3 monthly follow-up sessions in remote format. Focus groups were conducted at the end of our programme for each category of the 42 participants who experienced shared meditation based on 5 preselected open-ended questions. Responses were transcribed and analysed using NVivo software. Four salient themes were identified attesting that shared meditation: (1) was a positive experience, with physical and psychological benefits, even though requiring much commitment, (2) provided an experience enabling them to see themselves as people rather than just patients, (3) allowed them to rethink their lives by reconsidering their relationship with themselves and their disease, and (4) improved their relationships, not only with carers in the therapeutic setting but also outside it, with third parties. Their feelings of stigmatisation linked to the disease were attenuated. Improvement of psychosocial skills was reported as a major benefit of shared meditation. Beyond the positive effects on well-being, shared meditation could enable patients and others to develop a sense of social connectedness and to nurture a sense of common humanity. Our qualitative data provide valuable insights into how shared meditation can be implemented, not only within the care setting but also within the community at large.<b>Trial Registration</b>: ClinicalTrials.gov NCT06041607 registered: 09/18/2023.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261439128"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13084007/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147673036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Traditional Chinese Medicine Enhances Survival in Cancer Patients on Immunotherapy or Chemotherapy.","authors":"Tsung-Yun Hsieh, Sheng-Yin To, Cho-Hao Lee, Sunny Jui-Shan Lin, Li-Ting Kao","doi":"10.1177/15347354261494126","DOIUrl":"https://doi.org/10.1177/15347354261494126","url":null,"abstract":"<p><p>Integrating Traditional Chinese Medicine (TCM) with Western medical treatments enhances cancer patients' survival rates and quality of life. However, there is a lack of large-scale studies on the integration of TCM with immune checkpoint inhibitors (ICIs) or chemotherapy in cancer treatment. This retrospective cohort study analyzed data from the Taiwan National Health Insurance Research database and Taiwan Cancer Registry, including 2,512 patients treated with ICIs and 130,010 with chemotherapy between January 1, 2019, and June 30, 2021. Patients receiving TCM were classified as TCM users, while those who did not were nonusers. The primary outcome was all-cause mortality, assessed using Cox proportional hazards regression to estimate hazard ratios (HR) with 95% confidence intervals (CI), adjusting for demographics and comorbidities. Among ICI-treated patients, TCM users (n=720) had lower mortality rates than nonusers (n=1,792), with an incidence of 45.84 vs. 83.72 per 100 person-years (adjusted HR: 0.58; 95% CI: 0.51-0.66). Similarly, in chemotherapy-treated patients, TCM users (n=51,292) had reduced mortality (11.54 vs. 24.86 per 100 person-years; adjusted HR: 0.59; 95% CI: 0.57-0.60). These associations remained consistent across subgroup and sensitivity analyses. Commonly used TCM herbs included <i>Hedyotis diffusa</i> Willd (Bai Hua She She Cao), <i>Scutellaria barbata</i> (Ban Zhi Lian), and <i>Astragali</i> Radix (Huang Qi). These findings suggest that TCM use alongside ICIs or chemotherapy is associated with lower mortality, even after adjusting for confounders. Further prospective studies are needed to confirm these results and explore underlying mechanisms, advancing integrative cancer care.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261494126"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149109128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Shugan-Liangxue Prescription Inhibits Immune Escape Against Breast Cancer by Regulating Tryptophan Metabolism.","authors":"Youzhan Yang, Jinyu Liu, Runjia Shi, Xiaoya Li, Shuang Li, Yulin Lin, Yueqi Wang, Dayong Cai, Zhiqiang Cheng, Xin Zhao","doi":"10.1177/15347354261494127","DOIUrl":"https://doi.org/10.1177/15347354261494127","url":null,"abstract":"<p><p>ObjectiveTryptophan metabolism plays a pivotal role in promoting tumor progression by modulating immune escape in breast cancer (BC). Shugan-Liangxue prescription (SLP), a traditional Chinese medicine, has shown beneficial effects in enhancing antitumor immunity for BC treatment. This study aims to investigate the effect of SLP on tryptophan metabolism in BC and to explore the underlying mechanisms.MethodsThe immunopharmacological BC model in rats was established by chemical carcinogen induction and complete freund's adjuvant perturbations and treated with SLP. Tamoxifen and other metabolism-associated drugs were used as controls. The therapeutic efficacy of SLP was evaluated by tumor volume, weight, and oncocyte proliferation. Serum cytokines and subsets of immune cells in the spleen were measured to evaluate the anti-tumor immunity. Metabolite levels and expressions of signal molecules of tryptophan metabolic pathway were measured to explore the mechanisms.ResultsOur findings demonstrated that SLP treatment significantly inhibited tumor growth and tumor cell proliferation, and enhanced antitumor immunity by promoting Th1 polarization, increasing cytotoxic immune cells (CD8+ T cells, NKG2D+ NK cells), and reducing inhibitory immune cells (Foxp3+ Tregs, NKG2A+ NK cells, M2 macrophages) in the spleen. Additionally, SLP regulated glucose and lipid metabolism, as evidenced by reduced serum glucose and non-esterified fatty acid levels. SLP suppressed tryptophan catabolism by down-regulating expression of IDO1 and AhR and reducing kynurenine levels.ConclusionsIn summary, correlative analyses suggest SLP may mitigate breast cancer immune escape partially via the Trp metabolic pathway to boost anti-tumor immune surveillance, and its immunomodulatory activity is potentially linked to glucose and lipid reprogramming. While our findings support the involvement of the Trp-Kyn-AhR axis, causal verification via pathway rescue and inhibition assays is still needed.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261494127"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149164293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjuvant Chemotherapy with Traditional Chinese Herbal Granules Versus Placebo in Resected Non-Small Cell Lung Cancer: Updated Survival Analysis of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.","authors":"Yichao Wang, Lijing Jiao, Zhiwei Chen, Jianfang Xu, Jiaming Che, Hai Huang, Lei Zhang, Xiaoyong Shen, Yi Yang, Tiancheng Zhao, Jie Zhang, Di Zhou, Qin Wang, Jialin Yao, Wenxiao Yang, Chenbing Sun, Jiaqi Li, Ling Bi, Rongzhen Ding, Ian Goodfellow, Yabin Gong, Ling Xu","doi":"10.1177/15347354251409081","DOIUrl":"10.1177/15347354251409081","url":null,"abstract":"<p><strong>Background: </strong>The NALLC trial (NCT01441752) demonstrated that postoperative adjuvant chemotherapy combined with traditional Chinese medicine (TCM) improved the quality of life (QoL) and survival in resected stage Ib-IIIa non-small-cell lung cancer (NSCLC) patients. This report updates disease-free survival (DFS) and other key outcomes.</p><p><strong>Methods: </strong>Between December 2012 and August 2015, 334 patients were randomized to receive either adjuvant chemotherapy plus traditional Chinese herbal granules (n = 167) or adjuvant chemotherapy plus placebo (n = 167) across 7 centers. Patients continued herbal granules or placebo daily until chemotherapy completion. DFS updates data was conducted in the intention-to-treat (ITT) population.</p><p><strong>Results: </strong>The median follow-up was 116.87 months. Median DFS was 71.83 months for the TCM group versus 43.60 months for the control (HR: .86; 95% CI: .64-1.15; <i>P</i> = .31). Two-year and 5-year DFS rates were 73.60% and 50.16% for TCM, compared to 67.45% and 44.08% for the control (<i>P</i> = .23). Median overall survival (mOS) was not reached in either group, with 75% OS at 63.40 months for TCM and 53.67 months for the control. Five-year OS rates were 76.15% for TCM and 69.81% for the control (<i>P</i> = .23). Subgroup analysis showed stage Ib patients benefited from TCM in both DFS (HR: .51; <i>P</i> = .02) and OS (HR: .34; <i>P</i> = .01).</p><p><strong>Conclusions: </strong>Adjuvant chemotherapy combined with TCM showed a potential trend toward improved DFS in early-stage NSCLC patients.</p><p><strong>Trial registration: </strong>This trial was registered with Clinical.</p><p><strong>Trials: </strong>gov (Number: NCT01441752, July 14, 2011).</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354251409081"},"PeriodicalIF":2.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12847656/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146051932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase 1 Trial of <i>Withania somnifera</i> Leaf Extract (RH324) in Advanced Non-Small Cell Lung Cancer Including [¹⁸F]FDG PET/CT as a Short-Term Metabolic Biomarker to Assess Efficacy: A Novel Model for Assessment of Complimentary Therapies in Early Phase Human Clinical Trials.","authors":"Jin Uk Heo, Santosh Rao, Herbert B Newton, Afshin Dowlati, Raymond F Muzic, Arash Kardan","doi":"10.1177/15347354251410182","DOIUrl":"10.1177/15347354251410182","url":null,"abstract":"<p><strong>Background: </strong><i>Withania somnifera</i> (WS), commonly known as ashwagandha, has been used in the traditional medical system of India. It has shown significant activity against numerous solid tumor varieties in pre-clinical in vitro and in vivo studies. This study focuses on RH324 (ReHeva Biosciences, Columbus, OH), a pharmaceutical-grade formulation derived from WS, which has received FDA allowance for clinical development as a botanical drug in the treatment of cancer.</p><p><strong>Methods: </strong>A phase 1 open label dose ranging study of oral RH324 in advanced non-small cell lung cancer (NSCLC) was conducted. The primary endpoint of the study was assessment of short-term safety and tolerability. An exploratory aim was assessment of RH324's anti-neoplastic effects as measured by changes in tumor metabolism using [¹⁸F]-labeled 2-fluoro-2-deoxy-D-glucose (FDG)-PET/CT scans performed before and after completing a 28-day RH324 monotherapy regimen. A total of 9 patients were enrolled, 5 of which completed the trial, including imaging, and were evaluable.</p><p><strong>Results: </strong>All study safety and tolerability primary endpoints were met. Analysis revealed notable response rates across different SUV parameters (SUV_max, SUV_mean, and SUV_peak) and there were no new metastatic lesions identified, further supporting RH324's anti-neoplastic effects.</p><p><strong>Conclusion: </strong>RH324 was safe and well tolerated as a monotherapy in advanced NSCLC. FDG-PET/CT provided a novel methodology as a short-term metabolic endpoint with an in vivo biomarker assessment of potential clinical efficacy using a metabolic surrogate of disease activity. This approach offered deeper insights into tumor metabolism and heterogeneity, underscoring the potential of RH324's anti-neoplastic effects in treating refractory NSCLC.</p><p><strong>Clinical trial registration: </strong>ClinicalTrials.gov, Identifier: NCT05580172, Registered on October 17, 2022.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354251410182"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12905094/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146179479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NUTRISCORE: A Novel Nutrition-Based Nomogram to Predict Severe Neutropenia After Adjuvant Chemotherapy in Gastric Cancer.","authors":"Chun Gao, Li Zhu, Yi Xin Tong, Sheng Zhang","doi":"10.1177/15347354261447851","DOIUrl":"10.1177/15347354261447851","url":null,"abstract":"<p><strong>Background: </strong>To develop and validate a clinically applicable nomogram (NUTRISCORE) predicting severe neutropenia (Grade 3/4) across cycles 2 to 8 of adjuvant chemotherapy in gastric cancer.</p><p><strong>Methods: </strong>This retrospective cohort study analyzed 391 patients receiving postoperative adjuvant chemotherapy (CAPEOX/XELOX/SOX) following curative laparoscopic D2 gastrectomy. Cohorts were stratified into derivation (n = 318; 1518 cycles) and validation (n = 73; 356 cycles) sets. Generalized Estimating Equations (GEE) were used to account for within-patient correlation of multiple cycles. Multivariable logistic regression identified independent predictors, with subsequent nomogram construction using R. Model performance was quantified through AUC-ROC and decision curve analysis (DCA).</p><p><strong>Results: </strong>Four predictors emerged: age > 60 years (OR = 2.1, <i>P</i> < .01), prealbumin ≤ 180 mg/L (OR = 3.4, <i>P</i> = .002), PNI < 45 (OR = 2.8, <i>P</i> = .008), and prior cycle neutropenia (OR =4.7, <i>P</i> < .001). The nomogram achieved AUCs of 0.825 (95% CI 0.789-0.860) and 0.810 (0.783-0.835) in derivation and validation cohorts, with DCA confirming clinical utility across threshold probabilities (4%-65% in derivation, 3%-63% in validation), supporting its use for guiding G-CSF prophylaxis at clinically relevant risk thresholds (>15%).</p><p><strong>Conclusions: </strong>We establish a nutrition-centric predictive tool for severe neutropenia, demonstrating robust accuracy in stratifying chemotherapy toxicity risk. This model directly informs personalized prophylactic strategies, warranting prospective multicenter validation.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261447851"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13332284/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148375792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploratory and Pioneering Study on Courses Involving Complementary and Alternative Medicine (CAM) Within an Integrative Approach at University of Messina Medical School.","authors":"Giuliana Ciappina, Enrica Toscano, Valentina Urzì Brancati, Giordana Di Mauro, Irene Campo, Letteria Minutoli, Alessia Bignucolo, Irene Cacciola, Giovanna Spatari, Angela Alibrandi, Domenico Antonio Restivo, Silvana Parisi, Natalia Catalano, Pierluigi Consolo, Massimiliano Berretta","doi":"10.1177/15347354251398860","DOIUrl":"10.1177/15347354251398860","url":null,"abstract":"<p><strong>Objective: </strong>Complementary and alternative medicine (CAM) is widely used by patients with chronic diseases, including cancer, but many physicians still have little knowledge about these medical methods and/or do not believe in their efficacy. This leads to inadequate doctor-patient communication and self-prescription of CAM with a high risk of interaction with standard cancer treatments. Information about CAM should be planned at all levels of medical education, starting from university, to promote the use of CAM among specialists. The primary objective of this study, conducted between October 2023 and February 2024, was to assess the opinion and impact of learning about CAM in future graduating physicians.</p><p><strong>Methods: </strong>One hundred and sixty medical students attended a 2-hour CAM academic training course; they also completed an anonymous 35-item questionnaire divided into 2 sections. The items included in the first section investigated their attitudes toward CAM. The second part of the survey investigated the students' opinion about the course they had attended and re-evaluated their knowledge of CAM.</p><p><strong>Results: </strong>Of the 160 participants, 79.4% were aware of the existence of other forms of medicine besides conventional medicine, and the most well-known CAM were Oriental and Chinese medicine (48.8%), homeopathy (8.1%), and acupuncture (5%). About 58.4% percent of participants agreed that universities should teach CAM, 51.3% believed that different medical approaches can coexist, and 78.1% did not consider Western medicine to be the only therapeutic option. One hundred percent found the teaching of CAM useful, 88.8% agreed that CAM should be taught in all medical/health/biological degrees, and 88.1% would propose an integrative approach.</p><p><strong>Conclusion: </strong>Clinical practice can be significantly improved by introducing CAM into university training programs. This will meet the educational needs of modern and innovative medicine, with the hope that in the future, physicians will be able to provide patients with tailored treatments choosing their options from both conventional and alternative medicine and will discourage patients from seeking treatment and medical advice from non-medical practitioners.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354251398860"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13477524/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148758852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reporting of Adherence-Related Information in Randomized Controlled Trials of Oral Chinese Herbal Medicine for Cancer: A Cross-Sectional Study.","authors":"Xuechen Geng, Qinchang Zhang, Qianqian Bu, Yuquan Tao, Dong Zhang, Ling Li, Weizhong Li, Dan Dong, Shuhang Kan, Yanmei Liu, Liu Li, Haibo Cheng","doi":"10.1177/15347354261491385","DOIUrl":"https://doi.org/10.1177/15347354261491385","url":null,"abstract":"<p><p>BackgroundAdherence is important for the internal validity of randomized controlled trials (RCTs), but adherence-related reporting in oral Chinese herbal medicine (CHM) RCTs for cancer has not been systematically examined. This study assessed reporting practices before the release of the CONSORT 2025 statement and explored factors associated with intervention completion.MethodsPubMed, Web of Science, EMBASE, and the Cochrane Library were searched for eligible studies published between January 2010 and April 2025. Study characteristics, adherence-related reporting, monitoring methods, and intervention completion were extracted. Binary logistic regression identified factors associated with reporting of adherence-related information. In parallel-group RCTs using CHM only in the intervention group, beta-binomial regression was used as the primary model to assess factors associated with intervention completion.ResultsA total of 113 studies were included, and 51 (45.1%) reported adherence-related information. English-language publication, higher modified Jadad score, and reporting of adherence monitoring methods were associated with reporting of adherence-related information. Only 24 studies (21.2%) described adherence monitoring methods, with diary cards being the most common. Mean intervention completion across the 51 studies was 93.4%. In 43 parallel-group RCTs, placebo use (OR = 0.38, 95% CI: 0.24-0.60; <i>P</i> < 0.001) and syndrome differentiation-guided treatment adjustment (OR = 0.58, 95% CI: 0.37-0.91; <i>P</i> = 0.019) were associated with lower intervention completion in the CHM intervention group, whereas solid dosage forms were associated with higher intervention completion (OR = 2.11, 95% CI: 1.26-3.55; <i>P</i> = 0.005). The directions of the associations were generally consistent across sensitivity analyses.ConclusionBefore the release of CONSORT 2025, adherence-related reporting in oral CHM RCTs for cancer was inadequate and non-standardized. Placebo use, syndrome differentiation-guided treatment adjustment, and oral dosage form were associated with intervention completion. These findings may inform adherence reporting and the design of future CHM trials.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261491385"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149165984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}